Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


AbbVie delays pain-free Humira

Posted 21 September 2020

AbbVie is working towards the potential PBS listing of its new Humira formulation in eight months time, despite the pain-free formula having been available overseas for years and a local petition attracting 26,000 signatures from Australian patients calling for funded access.

AbbVie has copped criticism from patients for failing to expedite the "pain-free" version of Humira, saying the company is enjoying an "incredibly lucrative monopoly of the treatment... in Australia".

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
UPDATES: UNICEF stockpiling one billion syringes
Approvals Action
Shakeup for insulin
New biosim plus hypertension and herpes generics
Top of the Hill
Avoiding the Emperor's mistake
Not everyone is convinced about industry's budget win